Richard C. Young & CO. LTD. Trims Holdings in Sanofi (NASDAQ:SNY)

Richard C. Young & CO. LTD. lowered its stake in shares of Sanofi (NASDAQ:SNY) by 27.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 34,694 shares of the company’s stock after selling 13,159 shares during the period. Richard C. Young & CO. LTD.’s holdings in Sanofi were worth $1,999,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of SNY. Boston Partners grew its stake in shares of Sanofi by 0.3% in the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after buying an additional 33,657 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares during the period. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in shares of Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after acquiring an additional 246,224 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in Sanofi by 26.5% in the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after acquiring an additional 673,172 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Finally, Argus increased their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Performance

NASDAQ:SNY opened at $47.97 on Monday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The firm’s fifty day simple moving average is $54.65 and its 200-day simple moving average is $52.23. The stock has a market cap of $121.74 billion, a PE ratio of 24.47, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the prior year, the firm earned $2.55 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. Analysts expect that Sanofi will post 4.29 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.